Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in People Living with HIV (PLWH)

Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in People Living with HIV (PLWH)

While SARS-CoV-2 has transitioned to an endemic phase, infections caused by newly emerged variants continue to result in severe, and sometimes fatal, outcomes or lead to long-term COVID-19 symptoms. Vulnerable populations, such as PLWH, face an elevated risk of severe illness. Emerging variants of S...

Full description

Bibliographic Details
Main Authors: Maxim Cherneha, Isabel Zydek, Peer Braß, Johannes Korth, Sarah Jansen, Stefan Esser, Christina B. Karsten, Folker Meyer, Ivana Kraiselburd, Ulf Dittmer, Monika Lindemann, Peter A. Horn, Oliver Witzke, Laura Thümmler, Adalbert Krawczyk
Format: Article
Language:English
Published: MDPI AG 2024-07-01
Series:Vaccines
Subjects:
COVID-19
PLWH
mRNA-Vaccine
SARS-CoV-2
immunity and immunocompromised
Online Access:https://www.mdpi.com/2076-393X/12/7/785

Internet

https://www.mdpi.com/2076-393X/12/7/785

Similar Items